Bio-Thera Solutions, a global biotechnology company based in Guangzhou, China, says it began a phase 1 study of BAT2506, a proposed golimumab biosimilar referencing Simponi.
Bio-Thera Solutions, a global biotechnology company based in Guangzhou, China, says it began a phase 1 study of BAT2506, a proposed golimumab biosimilar referencing Simponi.
The study compares the pharmacokinetics and safety of BAT2506 to golimumab sourced from the European Union, with each participant receiving either a single subcutaneous dose of BAT2506 or golimumab. The randomized, double-blind, 2-arm, parallel group study is expected to enroll about 182 healthy volunteers.
“Initiating our [phase 1] clinical trial for BAT2506, our proposed biosimilar for Simponi, represents the fourth biosimilar that Bio-Thera has advanced into clinical trials,” said Shengfeng Li, chief executive office of Bio-Thera Solutions, in a statement. “Bio-Thera is committed to bringing safe and effective biosimilars to patients around the world.”
The brand-name Simponi, developed by Janssen, is FDA approved to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis (AS), and ulcerative colitis. An anti—tumor necrosis factor therapy, golimumab is administered via a subcutaneous injection. Another formulation of golimumab, sold as Simponi Aria, is available for intravenous infusion.
Worldwide, Janssen saw sales of $563 million from the 2 formulations of Simponi, up 2.7% from the same quarter in 2018.
Bio-Thera Solutions is also developing other proposed biosimilars. Its proposed adalimumab biosimilar, BAT1406, recently met its primary end point of equivalent efficacy to reference adalimumab, Humira, in a phase 3 trial conducted in patients with active AS.
It is also developing a proposed bevacizumab biosimilar, BAT1706, referencing Avastin, and BAT1806, a proposed tocilizumab (Actemra) biosimilar. BAT1806 is also in a phase 3 trial.
Study Documents HCPs’ Experiences of a Mandatory Switch to Inform Future Transitions
December 2nd 2023A survey explores the experiences of health care providers (HCP) throughout the transition process following a mandatory switch from the adalimumab originator (Humira) to a biosimilar in New Zealand in 2022.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
Dr Fran Gregory Sizes Up the US Adalimumab Market: Will Biosimilars See Success?
September 17th 2023On this episode of Not So Different, Fran Gregory, PharmD, MBA, vice president of emerging therapies at Cardinal Health, analyzes the adalimumab market so far in the United States and provides insight into how the market needs to adapt to accept these products and ensure lower drug costs for patients.
Public Payer in Poland Saves €243 Million by Using Biosimilar TNF Inhibitors
November 11th 2023The use of biosimilars of tumor necrosis factor (TNF) inhibitors within Poland’s public payer saved over €243 million from 2013 to 2021, with about 68% of that coming from the rheumatic musculoskeletal diseases alone.
Real-World Data Confirm Safety, Efficacy of CT-P13 in Inflammatory Diseases
November 9th 2023A real-world analysis from Japan confirmed that CT-P13, an intravenous infliximab biosimilar, had comparable safety and efficacy to the reference product (Remicade; infliximab) in patients with immune-mediated inflammatory diseases.